Can Tenet Healthcare Sustain Growth Despite Lower Surgical Volumes?

Tenet Healthcare reported 6.8% revenue growth to $5.63 billion despite lower surgical volumes, as USPI revenue per case rose 6.3% and ambulatory adjusted EBITDA increased 8.8% to $542 million. Hospital adjusted EBITDA climbed 22.3% to $762 million, lifting margin 240bps to 18.0%, supported by 2.6% adjusted-admission growth, 3.3% higher revenue per admission, and Medicaid supplemental payments. Tenet raised 2026 adjusted EBITDA guidance to $4.83-$5.03 billion and expects hospital adjusted admissions to rise 1-2% and USPI same-facility revenue to grow 3-6%.

Analysis

THC’s earnings quality is improving only if price/mix persists without requiring incremental labor or physician subsidies. The key sensitivity is that ambulatory pricing has offset modest case erosion; this is favorable near term, but it makes the multiple more exposed to payer pushback in 2027 contracting and to a normalization in high-acuity mix. The hospital margin step-up also contains a non-core reimbursement tailwind, so investors should separate recurring operational leverage from state/federal supplemental-payment variability.

Competitive read-through is constructive for HCA and UHS, but not symmetrical. HCA’s broader scale and stronger commercial payer exposure provide greater ability to monetize acuity, while UHS has the cleaner behavioral-health growth vector and less dependence on elective surgical throughput. THC’s USPI platform remains strategically valuable because ASCs can take share from hospital outpatient departments, but falling same-facility cases would become a concern if they persist for two additional quarters: it could indicate physician alignment or local demand issues rather than benign mix rotation.

The consensus risk is not volume alone; it is the interaction of weaker elective utilization, payer utilization-management scrutiny, and a potentially tougher Medicaid reimbursement backdrop. Over the next 1-3 months, raised guidance can support estimates and share performance, but after a substantial relative run THC needs further upward revisions rather than merely delivery. Over 6-18 months, outpatient migration favors high-quality ASC operators, yet acquisition-driven expansion can dilute returns if purchase multiples rise or integration costs reaccelerate.

Key Decisions for Investors

• Maintain a tactical long THC position into the next earnings/estimate-revision window (1-3 months), but size below benchmark conviction after the rerating. Target upside requires the upper half of EBITDA guidance and continued ASC revenue-per-case growth; exit or hedge if USPI same-facility cases decline more than 3% for a second consecutive quarter or guidance is not raised.
• Express the sector view through long HCA / short THC in equal-dollar terms for 3-6 months if THC trades materially above its recent relative valuation range. HCA offers a more diversified acute-care earnings base; the pair benefits if THC’s pricing/mix premium normalizes while hospital demand remains solid. Cover if THC demonstrates accelerating case growth alongside stable margins.
• Keep UHS on watch rather than chase: initiate only following evidence that behavioral-health growth converts into sustained margin expansion, not just revenue intensity. A long UHS versus a broad provider-services ETF can work over 6-12 months if behavioral EBITDA guidance rises and labor costs remain contained.
• Monitor Medicaid supplemental-payment disclosures and commercial reimbursement commentary at each company’s next call. Any reduction in state-program support, adverse utilization-management trend, or deceleration in revenue per admission/case is the primary falsifier for the group’s current earnings-momentum thesis.